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Abstract
The Aurora-A kinase regulates cell division, by controlling centrosome biology and spindle assembly. Cancer cells often
display elevated levels of the kinase, due to amplification of the gene locus, increased transcription or post-translational
modifications. Several inhibitors of Aurora-A activity have been developed as anti-cancer agents and are under evaluation in
clinical trials. Although the well-known mitotic roles of Aurora-A point at chromosomal instability, a hallmark of cancer, as
a major link between Aurora-A overexpression and disease, recent evidence highlights the existence of non-mitotic functions
of potential relevance. Here we focus on a nuclear-localised fraction of Aurora-A with oncogenic roles. Interestingly, this
pool would identify not only non-mitotic, but also kinase-independent functions of the kinase. We review existing data in the
literature and databases, examining potential links between Aurora-A stabilisation and localisation, and discuss them in the
perspective of a more effective targeting of Aurora-A in cancer therapy.
Introduction
Aurora kinases are a family of serine/threonine kinases
essential for mitotic execution in all eukaryotes. The cen-
trosome localised vertebrate member of the family, Aurora-
A, was originally named STK15/BTAK (Breast Tumour
Amplified Kinase) due to its overexpression in breast cancer
[1]. Aurora-A is involved in the centrosome maturation
process and contributes to the activation of the PLK1
kinase, thus promoting the transition from G2 to mitosis
[2, 3]. Aurora-A then exerts its control of mitotic progres-
sion by phosphorylating several targets. Upon autopho-
sphorylation on Thr288, along with binding to activating
partners among which TPX2 plays a major role, Aurora-A
acquires a fully active conformation and regulates the
assembly of the mitotic spindle from both centrosomes and
chromosomes [3, 4]. Mitotic roles of Aurora-A are widely
studied and have been extensively reviewed elsewhere (see
for example [3, 5]), while interphase functions in non-
transformed and cancer cells are emerging [6].
Aurora-A undergoes cell cycle regulation, with increased
levels in late S and G2 phases, and a peak in mitosis, fol-
lowed by proteasome-dependent degradation at mitotic exit;
nonetheless, recent evidence points out the existence of an
interphase pool of Aurora-A in specialised, non-transformed
cells, exerting physiological non-mitotic functions at the
G0/G1 phases of the cell cycle. It is involved in primary
cilium disassembly in ciliated cells, neurite outgrowth in
post-mitotic neurons and in the formation of the DNA pre-
replication complex (recently reviewed by [6]). Aurora-A
also regulates mitochondrial morphology and dynamics
throughout the cell cycle [7, 8], through a phosphorylation
cascade that includes RALA/RALBP1 and cyclin B/CDK1
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and that culminates in the phosphorylation of DRP1, a
protein acting in mitochondrial fragmentation.
Aurora-A increased levels have been reported in various
types of cancer such as neuroblastoma, lymphoma, breast,
colorectal, ovarian and prostate cancers [9, 10]. Indeed,
since its discovery, it was proposed as an oncogene based
on the observation that its overexpression was sufficient to
induce NIH/3T3 murine cell transformation [11], although
subsequent studies have highlighted the relevance of the
cellular background for Aurora-A’s transforming potential
(reviewed by [12]). Although amplification of the chro-
mosomal region 20q13, where AURKA gene is located,
frequently occurs in cancer cells [12–14], transcriptional
and/or post-translational alterations can also represent pos-
sible routes to increased Aurora-A levels [15, 16]. High
Aurora-A levels were shown to correlate with highly pro-
liferative cancers, with epithelial-mesenchymal transition
[15, 17], with drug-resistance [18–20] and tumour metas-
tasis formation [15, 21]. The relevance of Aurora-A in
cancer has driven efforts aimed at exploiting the kinase as
therapeutic target: different kinase activity inhibitors (ATP-
competitive) are currently under investigation in clinical
trials, although poor efficacy has been shown despite pro-
mising preclinical data [19, 22, 23].
Interestingly, when Aurora-A is deregulated, it acquires
cancer-related roles that do not correspond to physiological
Aurora-A functions in normal conditions. Here we will
discuss recent evidence of non-mitotic nuclear and kinase-
independent roles of Aurora-A in cancer progression and
cancer cell stemness maintenance. We will analyse which
regulatory layers may underlie these interphase roles of
Aurora-A and how they can be affected in cancer. Finally,
we will explore the intriguing possibility that therapeutic
approaches based on Aurora-A inhibition are not targeting
the relevant pool of the kinase in these contexts, opening the
way for improved strategies that would take into account its
non-mitotic oncogenic functions.
Aurora-A nuclear localisation is required for
oncogene-mediated cell transformation and
self-renewal of cancer stem cells
Evidence of Aurora-A nuclear localisation in cancer exists
in cell lines from solid and haematological tumours [24–28]
and interestingly, Aurora-A appears to be overexpressed in
all of these conditions. Aurora-A localisation in six head
and neck cancer cell lines was assessed by western blot on
the nuclear fraction and by immunofluorescence and was
found inside the nucleus, which differs from its localisation
in non-transformed keratinocytes, where it is only cen-
trosomal [27]. Nuclear Aurora-A was also observed in
breast cancer, specifically in five patient-derived primary
cultures from breast cancer tissue and four breast cancer cell
lines (MDA-MB-231, Sk-br-3, SUM149 and BT549) [28].
Within the pathology database of the Human Protein Atlas
(https://www.proteinatlas.org/humanproteome/pathology)
we found widespread differences in apparent distribution of
Aurora-A between nuclear and cytoplasmic compartments
in the histological samples recorded, with certain cancer
types scoring more highly for nuclear localisation—notably
pancreatic, renal and liver—than others (Fig. 1). Interest-
ingly, we found that in the accompanying study matching
cancer transcriptomics to patient survival data [29], three of
the four cancer subtypes in which Aurora-A overexpression
was found to be prognostic were those showing the highest
tendency for exclusive nuclear localisation of Aurora-A.
Interestingly, nuclear Aurora-A has been proposed as a
prognostic marker for poor survival in breast cancer [24].
Specific experimental approaches where localisation can
be modulated were undertaken to directly address whether
this particular localisation contributes to Aurora-A onco-
genic ability. Tatsuka et al. [27] report that a fusion protein
Aurora-A-NES (Nuclear Export Signal) is actively exported
outside the nucleus. In BALB/c 3T3 A31-1-1 murine
fibroblasts, Aurora-A wild type, but not Aurora-A-NES,
was able to increase the frequency of oncogenic H-RasG12V-
induced transformation, indicating the relevance of Aurora-
A nuclear localisation [27]. Interestingly, K/H-RasG12V
mutants were able to yield high Aurora-A levels in lung,
ovarian and pancreatic cancer cells [30–32], as well as in
primary mouse embryonic fibroblasts, where this intrigu-
ingly corresponded to a significantly increased Aurora-A
nuclear/cytoplasmic ratio when compared to non-
transformed murine cells [28]. Together these observa-
tions suggest a positive regulatory loop between K/H-Ras
and Aurora-A, promoting cell transformation.
A more complex system to address the oncogenic role of
nuclear Aurora-A was used in breast cancer cell lines, where
Aurora-A depletion by RNA-interference (RNAi) results in
reduction of mammosphere formation and breast cancer stem
cells (BCSCs), identified as the CD24low/CD44high cell
population [28]. In order to distinguish the contribution of
nuclear Aurora-A in the regulation of the BCSC phenotype, a
fusion protein constituted by Aurora-A, the hormone-binding
domain of oestrogen receptor (ER) and a NES sequence
(Aurora-A-ER) was generated, which was reported to retain
kinase activity (as assessed by p-p53 and p-H3 signals [28]).
In this study, Aurora-A-ER localises in the cytoplasm, but,
after the administration of 4-hydroxytamoxifen (OHT), the
fusion protein re-localises inside the nucleus: this strategy
allows to control the accumulation of nuclear Aurora-A.
Importantly, only the nuclear translocation of Aurora-A-ER,
upon 4-OHT administration, was able to restore the CD24low/
CD44high population and mammosphere formation in
Aurora-A-depleted MDA-MB-231, SUM149 and BT549
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Triple Negative Breast Cancer (TNBC) cells, indicating that
Aurora-A nuclear localisation is required for breast cancer
proliferation and staminal potential [28]. Interestingly,
Aurora-A kinase inhibitors were not effective in suppressing
the CD24low/CD44high population in MDA-MB-231 cells
silenced for endogenous Aurora-A and expressing exogenous
Aurora-A-NLS (Nuclear Localisation Signal) [28], suggest-
ing that nuclear Aurora-A exerts kinase-independent
functions.
Taken together, these data highlight the existence of a
nuclear pool of Aurora-A in cancer cells and lay the foun-
dations for the comprehension of new mechanisms of
action, possibly kinase independent, through which Aurora-
A overexpression contributes to the transformed phenotype.
Aurora-A as transcriptional regulator and
target of Myc and FOXM1 in breast cancer
With the intent of clarifying the ‘non-canonical’ nuclear
interphase roles of Aurora-A in cancer stem cell self-
renewal, the intriguing possibility that the kinase could
work as a transcriptional regulator in breast cancer was
investigated [28, 33]. Expression of a chimeric version of
Aurora-A fused to the GAL4-DNA-binding domain was
able to yield the expression of a luciferase reporter starting
from a minimal promoter displaying GAL4-DNA-binding
sites, highlighting Aurora-A’s transactivation activity [28].
Authors identified a nine amino acid sequence (9aa TAD), a
domain that is already known to elicit transactivation
activity [34], in the region 238-246 of Aurora-A [28] within
the kinase domain, and showed that it is required for
Aurora-A transactivating functions.
In the search for target genes regulated by nuclear Aur-
ora-A, it was noted that nuclear overexpressed Aurora-A is
associated with upregulation of Myc and FOXM1 proteins
and mRNA levels in the BSCS CD24low/CD44high popula-
tion, as well as of the stem cell markers SOX2 and NANOG
[28, 33]. The well-known oncogenes Myc and FOXM1 are
transcription factors normally involved in cellular growth:
in particular the former is a ‘master regulator’, which con-
trols many aspects of differentiation (reviewed by [35, 36]),
stemness [37], metabolism [38, 39] and apoptosis [40],
while the latter, belonging to the forkhead box (FOX)
superfamily of transcription factors, is a protagonist of cell
cycle progression, regulating genes involved in G1/S as
well as G2/M transition and correct mitosis execution [41].
It is not surprising that the deregulation of these two tran-
scription factors culminates in tumour initiation and pro-
gression, and that the upregulation mediated by Aurora-A
may thus lead to altered signalling cascades in several types
of neoplasm.
Interestingly, Aurora-A overexpression yields increased
levels of Myc and FOXM1 independently of its kinase
Fig. 1 Meta-analysis of Aurora-A localisation. Locations scored as
‘nuclear’, ‘cytoplasmic/membranous’ or ‘cytoplasmic/membranous
and nuclear’ in the database (here we have removed the designation
‘membranous’ as misleading) are expressed as percentage of total
Aurora-A-positive samples for each tumour type (n ≥ 4).
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activity. Indeed, the wild-type kinase and inactive mutants
(Kinase Dead; D274N) equally induced the expression of
both oncogenes, while their levels decreased following
Aurora-A depletion, but not VX680- or MLN8237-
mediated inhibition [28, 33]. Intriguingly, despite the
same consequences on their expression, Aurora-A regulates
the transcription of Myc and FOXM1 through distinct
mechanisms (Fig. 2A).
MYCC gene is transcribed from two different promoters,
P1 and P2, with P2 being preferentially used under phy-
siological conditions, while in some cases, such as in Bur-
kitt’s lymphoma, a shift in P1/P2 promoter usage occurs
[42–44] resulting in altered regulation of Myc expression
and its increased levels. The nuclear fraction of Aurora-A,
but not the cytoplasmic one, induces a P1/P2 shift in pro-
moter usage, further supporting the notion that the nuclear
pool of the kinase has transcription activity and suggesting
that this MYCC regulation also occurs in BCSC [28].
Aurora-A lacks DNA-binding sites, and requires partners to
exert its transactivation transcription functions (Fig. 2A).
The ribonucleoprotein hnRNP K was identified as the key
mediator on the MYCC promoter, where an Aurora-A/
hnRNP K complex was revealed by re-ChIP assays.
Depletion of hnRNP K impairs Aurora-A recruitment on the
MYCC promoter, but not vice versa. Consistently, nuclear
localisation of overexpressed Aurora-A does not lead to an
increase in the CD24low/CD44high cell population, nor to
MYCC promoter usage shift towards P1, upon hnRNP K
depletion. Thus, the kinase requires hnRNP K to target the
MYCC promoter and induce the BCSC phenotype [28].
Interestingly, a link between Aurora-A and hnRNP K
was previously shown [45], with the ribonucleoprotein
being phosphorylated by the kinase on serine 379, an event
that disrupts its interaction with p53, of which hnRNP K is
also a transcriptional co-activator [45], while not influen-
cing MYCC promoter activation [28]. Since p53 negatively
controls the expression of multiple cell cycle genes,
including MYCC [46, 47], this may represent an additional
route through which Aurora-A and hnRNP K regulate
MYCC expression (Fig. 2A, upper left box).
A similar transcription regulatory mechanism involves
Aurora-A and the FOXM1 oncoprotein, in BCSC pro-
liferation (Fig. 2A, upper right box). The region +1/+300
of the FOXM1 promoter is required for Aurora-A-mediated
transactivation [33]; interestingly, this region contains a
forkhead responsive element, suggesting a co-operation of
Aurora-A and FOXM1 itself on the FOXM1 promoter.
Supporting this hypothesis, reporter luciferase assays
showed that only in presence of FOXM1 can the kinase
regulate FOXM1 promoter transcription [33], similarly to
what was observed for Myc expression upon hnRNP K
depletion [28]. In turn, both FOXM1 and Myc are able to
bind the AURKA promoter and activate its transcription,
suggesting the existence of a positive feedback loop
(Fig. 2A), in which Aurora-A promotes FOXM1 and Myc
expression and vice versa [33, 48, 49]. Accordingly, their
expression patterns oscillate upon their respective depletion
or overexpression; interestingly, depletion of FOXM1 in
MDA-MB-231 (high Myc) breast cancer cells was able to
reduce not only Aurora-A levels, consistent with the
FOXM1 transcription regulation of AURKA gene, but also
Myc levels [33, 48]. These observations strongly suggest
the intriguing hypothesis that both Myc and FOXM1
pathways display an interdependency on Aurora-A, and
converge in a synergistic action on the CD24low/CD44high
BCSC phenotype.
Although further studies are needed to clarify the path-
ways activated downstream of interphase excess of Aurora-
A, evidence summarised so far clearly indicates that its
nuclear localisation correlates with oncogenic properties of
BCSC, at least partially due to positive regulation of Myc
[28] and FOXM1 [33] levels.
Aurora-A acts to promote stability of
oncoproteins
In addition to its involvement in oncogene transcription and
expression, Aurora-A was also shown to have a kinase-
independent role in the stabilisation of oncoproteins
required for cancer cell proliferation.
As for TNBC, in which Aurora-A plays a pivotal role in
maintenance of cancer cell proliferation in concert with
FOXM1, the kinase is important for the tumour growth of
high-risk MYCN-amplified neuroblastoma, a subtype of
neuroblastoma in which the MYCN gene amplification is
predictive of higher aggressiveness and poor outcome
[50–52]. In fact, shRNA-mediated depletion of Aurora-A
led to reduced cellular proliferation and colony formation in
both N-Myc- and FOXM1-addicted cancer cells [53, 54].
The reduction in FOXM1 and N-Myc levels is the critical
mechanism by which depletion of Aurora-A inhibits tumour
proliferation, as confirmation of its interdependence with
the two oncoproteins.
Intriguingly, for both neuroblastoma and TNBC, Aurora-
A appears to regulate the ubiquitination of the oncoprotein
in order to fulfil its pro-tumorigenic function in cancer cells.
High levels of Aurora-A increase the half-life of the N-Myc
protein by protecting it from proteasome-dependent degra-
dation [54–56], while a reduction in FOXM1 protein half-
life was reported following Aurora-A RNAi [53]. There-
fore, Aurora-A overexpression augments the oncogenic
expression profile of these oncoproteins by mediating their
stabilisation. Below, we summarise what has been clarified
about the mechanisms through which Aurora-A manages to
maintain high levels of N-Myc and FOXM1.
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Fig. 2 Aurora-A functions in regulating transcription and stability
of oncoproteins. A Aurora-A can increase Myc expression directly,
through promoter shift, in combination with hnRNP K; a potential
indirect effect, also mediated by hnRNP K, may also represent an
indirect Aurora-A contribution to elevated Myc levels. The right panel
schematises the transcriptional effect of Aurora-A on FOXM1 gene
expression. The dashed arrow indicates potential direct binding of an
Aurora-A/FOXM1 complex to the FOXM1 promoter. In turn, Myc and
FOXM1 can upregulate AURKA gene expression. B The N-Myc pro-
tein sequence is schematically represented on top; myc boxes and
DNA-binding domains are indicated, as well as the binding regions to
Aurora-A and FBXW7. FBXW7 recognises and ubiquitinates N-Myc,
inducing proteasome-mediated degradation (lower left panel). Aurora-
A binding protects N-Myc from FBXW7-mediated degradation (lower
right panel). Created with BioRender.com.
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A series of publications has described an important effect
of Aurora-A on N-Myc stability [54–57], and evidence
exists that this is true for Myc too [58]. In neuronal pro-
genitor cells, N-Myc is phosphorylated at T58 by GSK3β
after a priming phosphorylation at S62 by the mitotic cyclin
B/CDK1 complex [59]. N-Myc phosphorylated at both sites
is recognised by the E3 ubiquitin ligase FBXW7 and
marked for proteasomal degradation, with the T58A muta-
tion being sufficient to interfere with this process [60]. In
MYCN-amplified neuroblastoma, binding of Aurora-A to an
overlapping region reduces FBXW7 binding to N-Myc.
This results in N-Myc protein protection and stabilisation
[54, 56] (Fig. 2B). The capability of Aurora-A to stabilise
N-Myc is independent of its kinase activity, since eight
different mutant alleles of Aurora-A, all of which have been
previously reported to be deficient in kinase activity, were
able, as the wild-type kinase, to stabilise N-Myc [54].
Despite its stabilisation of N-Myc, Aurora-A appears to
promote the accumulation of ubiquitin conjugates on N-
Myc [54] (Fig. 2B). These may be so-called ‘unconven-
tional chains’ that are degraded less efficiently by the
proteasome with respect to K48-linked or branched poly-
ubiquitin chains [54, 61], or that may have functional sig-
nificance other than proteasome-mediated degradation and
specify an alternative fate for the N-Myc protein [62]. It is
therefore possible that Aurora-A interaction modifies the
balance of ubiquitin linkages on N-Myc by influencing
access of the ubiquitination machinery. We note that
UBE2C, an E2 enzyme whose coding gene is located, as is
the AURKA genomic locus, in the 20q chromosome arm
frequently amplified in tumours, may represent an inter-
esting candidate; indeed increased Aurora-A and UBE2C
levels in cancer positively correlate, with the two genes
occurring within cancer-related signatures, and an interac-
tion between them has been reported [63–65]. Moreover,
UBE2C is among the top ten genes with similar expression
pattern to Aurora-A in tumour cells, according to GEPIA
meta-analysis (http://gepia.cancer-pku.cn).
Yang et al. [53] proposed that Aurora-A binding to
FOXM1 reduces its ubiquitin-dependent turnover in breast
cancer cell lines. Similarly to what is described for N-Myc
in neuroblastoma, this Aurora-A function would be inde-
pendent of its kinase activity in TNBC, since the adminis-
tration of the Aurora kinase inhibitor VX680 in MDA-MB-
231 cells does not cause a reduction in FOXM1 protein
levels. A number of E3 ubiquitin ligases contributing to
FOXM1 regulation have been identified (reviewed by [66])
and it is not known yet which of these ubiquitination
pathways would be regulated by Aurora-A, and if the
mechanism would resemble that described for the better
known stabilisation effect on MYC family proteins.
Interestingly, the isoforms of FBXW7 used for experi-
mental demonstration of the competition between ubiquitin
ligase and Aurora-A for the binding to N-Myc (FBXW7α
and FBXW7γ) are localised in the nucleus [67], arguing that
the nuclear fraction of the kinase may be responsible for N-
Myc protein stabilisation. We also found evidence that
RNF168, an E3 ubiquitin ligase able to ubiquitinate
FOXM1 in breast cancer, displays nuclear localisation [68].
Despite no evidence yet existing to show that Aurora-A can
compete with FOXM1 ubiquitin ligases, it will be inter-
esting to investigate the potential interplay between nuclear
Aurora-A and RNF168 in regulating FOXM1 levels in
breast cancer.
Can Aurora-A mutations in cancer impact on
its localisation?
Despite several studies evaluating the oncogenic potential
of the nuclear localisation of Aurora-A, the import/export
trafficking of the kinase through the nucleus is poorly
explored and underlying mechanisms have not been clar-
ified. Nuclear accumulation of overexpressed Aurora-A-
GFP was observed to different extents depending on the
cellular system (HeLa versus Xenopus XL2 cells) and was
modulated by Leptomycin B administration, an inhibitor of
CRM1-mediated nuclear export [69]. Deletion analyses
indicated that the 333-383 region of the kinase is required
for nuclear accumulation of GFP-tagged Aurora-A. In this
work, the authors suggest that the portion required for
nuclear export lies within aa 1-333 [28], consistent with an
earlier study indicating that determinants of Aurora-A
cytoplasmic localisation lie in the N-terminal disordered
region of the kinase [69]. Interestingly, the first 30 aa of
Aurora-A are important for its mitochondrial localisation,
and have been proposed to contain an atypical mitochon-
drial targeting sequence, which for its full targeting function
requires proteolytic cleavage, post-translational modifica-
tions and/or specific interactions [7, 8].
Due to the importance of nuclear Aurora-A localisation
in mediating non-mitotic oncogenic functions, we looked
for evidence that link somatic mutations in the kinase, as
reported in the Catalogue Of Somatic Mutations In Cancer
[70, 71] (COSMIC v.92, https://cancer.sanger.ac.uk/
cosmic), and their reported localisation in the literature.
Overall, this search highlighted a cluster of mutations in the
disordered N-terminal and C-terminal regions (Fig. 3), but
with little or no indication of how these mutations affect
Aurora-A localisation. We found instead that several of the
mutations could be linked to Aurora-A interaction with
binding partners that could regulate either localisation or
stability of the protein (Fig. 3). Stability regulators might
have an indirect effect on localisation by promoting accu-
mulation or degradation in some subcellular compartments.
In addition, enhanced nuclear localisation of Aurora-A
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could result from altered activity of the nuclear import and
export machinery in specific cancer types. However, we did
not find evidence directly linking alterations in CRM1, the
only transport machinery factor so-far investigated for
Aurora-A localisation, with nuclear localisation of Aurora-
A in cancer databases.
We looked at mutations of residues that are known to
affect the ability of Aurora-A to interact with established
binding partners (Fig. 3). A well-characterised cancer-
associated mutation occurs at S155R (count of three, as of
v92 release, 2020), which shows decreased activity in vitro
as a result of loss of interaction with TPX2 and therefore
decreased Aurora-A at the mitotic spindle [72]. Our
research of the COSMIC database also highlighted S361*
truncation (count of five), which results in an inactive and
possibly unstable protein [72]. Furthermore, we found the
residue G136, which is involved in the interaction with
TACC3 during mitosis [73] to be mutated to A (count of
four). No information regarding the subcellular localisation
of this mutant could be found. Although these mutations
lead to decreased mitotic kinase activity of Aurora-A, which
depends on TPX2 and TACC3, their contribution to inter-
phase activity has not been assessed. We observe that
interaction with TPX2 (nuclear) and TACC3 (cytosolic)
could be parameters influencing the localisation of Aurora-
A in interphase, when kinase-independent roles may be
critical. Lastly, Aurora-A, like N-Myc, is a known substrate
for the FBXW7 ubiquitin ligase, shown to interact with
FBXW7 through residues T217 and E221 [74]. COSMIC
reveals small clusters of low count mutations in neigh-
bouring amino acids. S387 and S245 are phosphorylation
sites for GSK3β and are required for FBXW7 phospho-
degron recognition and ubiquitination; these are indeed
found mutated: S245P (one count) and S387L (two counts),
as well as additional surrounding residues (Y246H, three
counts; S249L, four counts; A385P/T, six counts; S388*/L,
three counts). The well-characterised interaction between
N-Myc and Aurora-A [54], discussed in a previous section,
has always been described as a stabilising role of Aurora-A
for N-Myc. Since both proteins are targets of the same F-
box protein, it is possible that they stabilise each other
by their interaction, with mutual protection from
FBXW7-mediated degradation augmenting their oncogenic
capability.
Two known allelic variants of Aurora-A that give rise to
F31I and I57V substitutions in its N-terminal disordered
region are also classed as somatic mutations associated with
cancer by the COSMIC database. Multiple studies testing
the significance of these alleles in cancer risk have led to
conflicting results, resolved by a meta-analysis which con-
cluded that I31 and V57 can each confer some ethnicity-
dependent risk [75]. The functional significance of I57V is
not known. Interestingly, the study which first associated
the Ile31 version of Aurora-A with increased aneuploidy
and stronger transforming properties in colon cancers [76]
showed the mutant protein to have reduced interaction with
Fig. 3 Overview of cancer-
associated Aurora-A
mutations and their functional
relevance. The mutation profile
of Aurora-A in cancer is shown,
together with the potential
partners whose physical or
functional interaction can be
influenced by the mutations.
Data from COSMIC v92 release
(August 2020) lists a total of 455
unique samples with mutations.
Created with BioRender.com.
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ubiquitin-conjugating enzyme UBE2N and strongly
reduced ubiquitination compared to the wild-type Phe31
version [76]. Since UBE2N is reported to be nuclear
(http://www.proteinatlas.org/, [77]), mutation to isoleucine
at position 31 might stabilise Aurora-A in a nuclear setting
to promote its transforming abilities. Finally, two N-
terminal prolines of Aurora-A also feature in the COS-
MIC list: P70L and P91L/Q (counts of two and five,
respectively). Whilst these mutants have not yet been
characterised, we note the recently published interaction
between Aurora-A and the E3 ligase von Hippel–Lindau
(VHL, [78]) that recognises its substrates through hydro-
xylated prolines [79]. Notably, the cancer-associated VHL
mutant is unable to degrade wild-type Aurora-A [78].
Together these investigations suggest that cancer-
associated Aurora-A mutations may affect the stability of
the kinase, or interaction with specific activators, that can,
in turn, be reflected in abnormal accumulation in distinct
cellular compartments.
Targeting Aurora-A kinase-independent
functions: a new therapeutic challenge
Given the potential of Aurora-A as a target for cancer
therapy, several inhibitors of its catalytic activity have been
developed over the years, in order to impair its mitotic
function and hence cell division [19, 22]. Indeed, all the
Aurora-A inhibitors that have entered clinical trials act as
ATP-competitors in the active site pocket, which is highly
conserved among human kinases. Despite great efficacy
(MLN8237 [80]), increased selectivity (LY3295668 [81])
and elevated potency (MK-5108 has an IC50 of 0.064 nM
[82]), the ATP-competitive inhibitors are well known for
exhibiting high promiscuity [83–85]. To date, they have not
met expectations raised in cellular studies.
How can the poor efficacy in clinical trials of classical
Aurora-A kinase inhibitors be explained? This gap has been
generally attributed to a relatively slow cell proliferation
rate in solid tumours and low selectivity [22, 86]. However,
the accumulating evidence for kinase-independent onco-
genic roles of nuclear Aurora-A suggest an alternative
explanation: that poor response to inhibitors instead reflects
a failure to target these kinase-independent roles. In this
view, ATP-competitive molecules may leave a relevant
Aurora-A population untargeted. Targeting not only kinase-
dependent Aurora-A functions, but also the emerging
kinase-independent ones, in order to suppress the oncogenic
ability of Aurora-A, appears as a new challenge in cancer
treatment. Possible innovative solutions may come from
combined therapies, disruption of Aurora-A interactions
with specific partners—including those influencing locali-
sation to specific subcellular sites—and total depletion of
the kinase, as we detail in the following paragraphs (sche-
matised in Fig. 4). Parallel studies aimed at characterising
Aurora-A status in clinical samples may help driving patient
stratification for a more effective response to such
treatments.
The combination of various treatments has been
demonstrated to be effective in breast cancer, since co-
inhibition of Aurora-A and FOXM1 effectively breaks the
feedback loop and interferes with the kinase and non-kinase
Fig. 4 Targeting of interphase
and mitotic functions of
Aurora-A. Aurora-A functions
in an interphase (left) or mitotic
(right) cell are schematised, with
indication of their dependence
on specifically localised Aurora-
A pools or on kinase activity.
On this basis, we propose that
different classes of Aurora-A
inhibitors (schematised on the
right and indicated by symbols
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functions of Aurora-A in TNBC, targeting, respectively,
both cytoplasmic (kinase dependent) and nuclear (kinase
independent) functions [33]. Results showed that combi-
natorial treatment with Aurora-A kinase inhibitor AKI6038
and FOXM1 inhibitor thiostrepton in MDA-MB-231 cells
yielded strong growth inhibition and suppression of colony,
mammosphere and xenograft tumour formation, with
respect to the single drugs administered alone, confirming
that inhibition of Aurora-A and FOXM1 synergistically
impairs the growth of BCSC [33].
Specific Aurora-A functions not relying on kinase
activity may also be impaired through inhibition of relevant
protein–protein interactions. A well-studied example is the
Aurora-A/N-Myc interaction in neuroblastoma. Indeed, N-
Myc-addicted neuroblastoma cells are sensitive to a specific
sub-class of ATP-competitive Aurora-A kinase inhibitors
able to induce a conformational change of the kinase,
resulting in disruption of the Aurora-A/N-Myc complex
[55–57]. The interaction between Aurora-A and N-Myc
requires an open conformation of the activation loop of the
kinase; conversely, these so-called conformation disrupting
inhibitors (CD-inhibitors), such as CD532 and Alisertib
(MLN8237), are able to block the activation loop in a
closed conformation [87], interfering with Aurora-A kinase
activity and, at the same time, with the Aurora-A/N-Myc
interaction. Although this has so far been shown only at
high concentrations of the drugs (low micromolar range)
with limited usefulness in vivo, it opens up the interesting
possibility of identifying Aurora-A kinase inhibitors able to
effectively block both kinase-dependent and N-Myc-related
kinase-independent functions [55–57].
The disruption of the Aurora-A/N-Myc complex allowed
by CD-inhibitors can also promote association of N-Myc
with other partners (RAD21, TOP2A, TFIIIC5) identified as
N-Myc interactors throughout the G1 phase of the cell cycle
[88]. Indeed, the Aurora-A/N-Myc interaction may act as a
protective mechanism during DNA replication to prevent
unscheduled transcriptional activity of N-Myc. Con-
sistently, CD-inhibitors induced increased levels of the
marker of recovery of collapsed replication forks phospho-
RPA32(S33), suggesting an S phase progression perturba-
tion [88]. Furthermore, it has been recently demonstrated
that N-Myc-dependent activity of Aurora-A is required for
the phosphorylation of histone H3 at S10 in S phase, to
antagonise N-Myc-dependent transcription–replication
conflicts. Co-inhibition of Aurora-A and ATR (required for
the stability of replication stalled forks) causes tumour
regression and immune system activation in MYCN-ampli-
fied neuroblastoma animal models [89]. In addition, N-
Myc-independent functions of Aurora-A on stalled forks
(kinase dependent [90]) and in the activation of replication
origins (kinase independent [91]) were recently discovered.
Interestingly, co-treatment with replication initiation
inhibitors and CD532, but not with compounds targeting
only the kinase activity of Aurora-A, synergistically acted
to arrest cell proliferation [91].
In the last few years, specific inhibitors of Aurora-A
binding to its major activator TPX2 have also been devel-
oped, with first cellular studies indicating that they are able
to inhibit Aurora-A autophosphorylation and interfere with
proper organisation of the mitotic spindle [92–94]. New
efforts directed towards disrupting interactions relevant to
interphase functions, and specifically nuclear functions of
Aurora-A, may constitute an interesting future perspective.
Another therapeutic approach that has recently gained
traction is the possibility of using small molecule drugs for
elimination of a target protein through ‘hijacking’ a cellular
E3 ligase to ubiquitinate it, leading to its ubiquitin-mediated
destruction by the 26S proteasome [95]. One of the clear
advantages of this strategy is to suppress all functions of a
target protein, and in the case of Aurora-A, both kinase-
dependent and -independent functions. Furthermore, the
catalytic nature of such small molecules (Proteolysis Tar-
geting Chimera, ‘PROTACs’), which act to mediate ubi-
quitination reactions through transient ternary complex
formation between the participants [96] rather than through
occupancy of a binding pocket, raises the prospect that they
can act at low doses and sub-optimal affinities for the target.
Two recent studies have tested PROTACs carrying the
MLN8237 ‘warhead’ linked to ligands for the E3 Cereblon
complex [97, 98]. These tools are found to efficiently
eliminate Aurora-A protein from the cell, resulting in phe-
notypes distinct from those produced by MLN8237 treat-
ment. Thus, Adhikari et al. [97] show that MLN8237-
treated cells arrested in mitosis, whilst PROTAC-treated
cells avoid mitotic arrest, arresting in S phase of the cell
cycle instead. Our own study shows that mitotic spindle
assembly can take place in the presence of an Aurora-A
PROTAC due to differential targeting of subcellular pools
of the target in mitosis that leaves a centrosomal pool intact
[3, 98]. Both studies indicate that targeting its kinase-
independent roles provides a novel therapeutic context for
drugging Aurora-A. Furthermore, a recent chemo-
proteomic study of more than 200 protein kinases identi-
fied Aurora-A as amongst those showing highest suscept-
ibility to targeted degradation [99], indicating the potential
nuclear oncogenic pool of Aurora-A as a promising ther-
apeutic target for the future design of targeted protein
degradation tools.
Although development of Aurora-A ATP-competitive
kinase inhibitors has so far dominated the approaches to
target mitotic Aurora-A in cancer, it is now clear that
oncogenic pools of the kinase which act in interphase and in
specific compartments—as for the nuclear functions
described in this review—may not be effectively targeted by
such strategies. Developing new strategies able to
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specifically reach these pools will contribute to better
exploiting Aurora-A as a target for anti-cancer therapies.
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